中华肾脏病杂志2024,Vol.40Issue(2) :146-157.DOI:10.3760/cma.j.cn441217-20231025-01037

长效红细胞生成刺激剂治疗肾性贫血中国专家共识(2024年版)

Chinese expert consensus on long-acting erythropoiesis-stimulating agents in the treatment of renal anemia(2024)

中国非公立医院协会肾病透析专业委员会共识专家组 刘必成 梅长林
中华肾脏病杂志2024,Vol.40Issue(2) :146-157.DOI:10.3760/cma.j.cn441217-20231025-01037

长效红细胞生成刺激剂治疗肾性贫血中国专家共识(2024年版)

Chinese expert consensus on long-acting erythropoiesis-stimulating agents in the treatment of renal anemia(2024)

中国非公立医院协会肾病透析专业委员会共识专家组 刘必成 1梅长林2
扫码查看

作者信息

  • 1. 东南大学附属中大医院肾脏病科,南京210009
  • 2. 海军军医大学第二附属医院(上海长征医院)肾脏病科,上海200003
  • 折叠

摘要

红细胞生成刺激剂(erythropoiesis-stimulating agents,ESAs)是临床上治疗肾性贫血的常用药物,目前可供临床医师选择的有短效ESAs和长效ESAs.短效ESAs在我国已广泛使用,历史悠久,国内外有众多指南共识.长效ESAs具有半衰期长、输注频次低、患者治疗依从性好等优势,近年来临床研究取得重要进展,但是尚缺乏长效ESAs临床规范使用的指导意见.为此,中国非公立医院协会肾病透析专业委员会组织相关专家制定了《长效红细胞生成刺激剂治疗肾性贫血中国专家共识》,本共识主要介绍了长效ESAs的分类、作用机制与药效学特点,在肾性贫血治疗中应用的适应证、时机、方案,特殊人群应用,不良反应及处理等,以指导长效ESAs类药物在肾性贫血治疗中的规范化使用.

Abstract

Erythropoiesis-stimulating agents(ESAs)are commonly used drugs in the treatment of renal anemia.There are currently two types of ESAs available to clinicians,including short-acting ESAs and long-acting ESAs.Short-acting ESAs have been used for decades in China,which are being widely accepted nowadays.Several professional societies have published consensus guidelines for the use and interpretation of short-acting ESAs worldwide in recent years.The advantages of long-acting ESAs include long half-life,low infusion frequency,good patient compliance,etc.There is still a lack of guidance on the clinical use of long-acting ESAs although important progress of long-acting ESAs has been made in clinical trials in recent years.Thus,the Society of Nephrology & Dialysis of China Non-Government Medical Institutions Association organized relevant experts to jointly formulate the"Chinese Expert Consensus on Long-acting ESAs in the Treatment of Renal Anemia".This consensus mainly introduces the classification,mechanism of action and pharmacological characteristics of long-acting ESAs,their indications,timing,administration protocols,application in special populations,adverse reactions and management in renal anemia.It is the hope of this concensus will guide the clinical use of long-acting ESAs in the treatment of renal anemia.

关键词

慢性肾脏病/肾性贫血/长效红细胞生成刺激剂/专家共识

Key words

Chronic kidney disease/Renal anemia/Long-acting ESAs/Expert consensus

引用本文复制引用

出版年

2024
中华肾脏病杂志
中华医学会

中华肾脏病杂志

CSTPCDCSCD北大核心
影响因子:1.182
ISSN:1001-7097
参考文献量93
段落导航相关论文